high blood pressure and glp 1 GLP-1 drugs tied to elevated risk of low episodes GLP-1 medications linked to hypotension

Careful dose adjustment is often needed

1 Total Randomized Trial Population Completer Population Upon discontinuation of treatment, patients are likely to regain weight 3-5 53% of Saxenda patients and 45% of patients on placebo completed the 3-year trial 3 The safety profile over 3 years was consistent with the profile at 1 year 3 Study 1 (3 years) 1,3 Results from a 160-week, randomized, double-blind, placebo-controlled study to evaluate the long-term safety and efficacy of Saxenda Adult patients with pre-diabetes and with a BMI of either 30, or 27 with at least 1 additional comorbidity were randomized to receive once-daily Saxenda (n=1,505) or placebo (n=749) in conjunction with a lifestyle modification program that included increased physical activity and a 500-kcal/day-deficit diet Patients underwent a 4-week dose-escalation period followed by 156 weeks on the full dose, with a 12-week off-drug observational follow-up period The study evaluated percentage of patients achieving weight loss of at least 5% of body weight at both 1 and 3 years Mean baseline body weight was 236.7 lb and mean BMI was 38.8 kg/m 2 In patients with obesity, losing weight causes changes in appetite hormones that can actually increase hunger and the desire to eat

While early studies found lower than usual levels of inositol in the cerebrospinal fluid of people with depression, later research did not support this finding

Nutritional information A dietary supplement / A nutrition supplement as a substitute for everyday diet, used for weight control